〔Abstract〕 Objective To explore the clinical effect of levosimendan on patients with heart failure with normal ejection fraction. Methods A total of 120 patients with heart failure with normal ejection fraction admitted to the People's Liberation Army Lushan Rehabilitation Center from May 2016 to May 2020 were selected as the research subjects, and divided into observation group and control group, with 60 patients in each group. The control group was treated with routine regimen, and the observation group was treated with routine regimen plus levosimendan. Results After treatment, the cardiac function indexes such as left ventricular end diastolic diameter (LVEDD), left ventricular short axis shortening rate (LVFS), left ventricular ejection fraction (LVEF), 6 min walking distance, and N-terminal pro-brain natriuretic peptide (NT-proBNP) of the two groups were significantly improved compared to before treatment, and the improvement range of the observation group was significantly better than that of the control group, and the differences were statistically significant (P < 0.05). The total effective rate of treatment in the observation group (95.00%) was higher than that in the control group (81.67%), and the difference was statistically significant (P < 0.05). The incidence of drug toxicity between the two groups was not statistically significant (P > 0.05). Conclusion Levosimendan can effectively improve the cardiac function of patients with heart failure with normal ejection fraction, and it is safe and effective.